Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for control of diabetes and complications thereof

A complication and composition technology, applied in the field of medicine, can solve problems such as liver and kidney function damage, gastrointestinal discomfort, metabolic disorder, etc., and achieve the effects of simple production process, prevention and treatment of chronic complications, and high benefits

Inactive Publication Date: 2017-09-22
青岛金海宝生物科技发展有限公司
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, western medicine hypoglycemic drugs such as insulin, biguanides, sulfonylureas and non-sulfonylureas are widely used clinically. Although the hypoglycemic effect is obvious, there are certain adverse reactions: arrhythmia, gastrointestinal discomfort, low Blood sugar, liver and kidney dysfunction, metabolic disorders, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] In this example, the preparation methods of sea cucumber polypeptide, kudzu root extract, brown algae oligosaccharide, water duckweed extract, trichosanthemi extract, pink extract, and ginkgo leaf extract are calculated on the basis of 1 kg of mass.

[0036] Weigh 1kg sea cucumber, wash, remove internal organs, add 600mL water to pulverize, add 1% neutral protease (sea cucumber quality), enzymolyze at 50°C for 10h, concentrate, alcohol precipitation, separate, spray dry to obtain refined sea cucumber peptide powder, set aside.

[0037] Weigh 1kg of fresh kelp, rinse, crush, stir in 0.1mol / L hydrochloric acid, 1.5mL HCHO at room temperature for 1h, filter, add 1% Na2CO3 to the filter residue, stir at 60°C for 1h, centrifuge to take the supernatant, concentrate, and precipitate with ethanol to obtain alginic acid The crude sodium product is degraded by enzyme, neutralized by alkali, and the crude product of sodium alginate is precipitated by ethanol to obtain the crude pro...

Embodiment 2

[0046] Effects of the pharmaceutical composition in this example on daily food intake and body weight of hyperglycemic animals induced by streptozotocin.

[0047] Take 40 Kunming SPF mice, half male and half female, fasting for 12 hours, drinking water freely, high-sugar and high-fat diet combined with several small doses of streptozotocin 80mg / kg (completed in 30 minutes) to establish models, and feeding for 7 days After fasting (without water) for 4 hours, take tail vein blood and measure blood sugar. Animals with a blood sugar value of 10-25 mmol / L are considered as animals with successful blood sugar modeling. They are randomly divided into 4 groups, model control group, positive control group (metformin hydrochloride tablets) ), the hypoglycemic drug combination group, the drug composition + positive group, and another 10 normal mice were taken as the normal group. After 35 days of continuous administration, the food intake and weight gain of the mice were measured.

[...

Embodiment 3

[0053] Effects of the hypoglycemic pharmaceutical composition of this example on fasting blood glucose, serum insulin and insulin resistance index in hyperglycemic animals induced by streptozotocin.

[0054] Select 40 male and female Kunming mice to model with 80mg / kg streptozotocin, select mice with successful blood sugar modeling, and randomly divide them into 4 groups, model control group, positive control group (metformin), drug combination group, drug combination + positive group, and another 10 normal mice were selected as the normal control group. After 35 days of continuous administration, the fasting blood glucose was measured by a blood glucose meter. After the mice were fasting for 3 to 5 hours, the tail blood was taken; , the serum was separated as usual, and the serum insulin content was determined according to the ELISA kit method; and the insulin resistance index (insulin resistance index, HOMA-IR) was calculated according to the formula (1).

[0055] HOMA-IR=se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for control of diabetes and complications thereof. The pharmaceutical composition comprises: sea cucumber polypeptide, alginate oligosaccharide, a kudzu vine root extract, a common duckweed extract, a radix trichosanthis extract, an extract of peach kernel and safflower, a ginkgo leaf extract, hirudin and nattokinase. The pharmaceutical composition provided by the invention can treat insulin resistant diabetes, the effective components are compounded to achieve better prevention and treatment effect on diabetes than single component, and the pharmaceutical composition also can prevent and treat some chronic complications associated with blood glucose rise. The pharmaceutical composition provided by the invention has the advantages of simple production process, low cost, high benefit, and obvious economic and social benefits.

Description

technical field [0001] The invention belongs to the technical field of medicine, and more specifically relates to a pharmaceutical composition for preventing and treating diabetes and its complications. Background technique [0002] Diabetes has become one of the three major chronic diseases that threaten human health. According to the statistics of IDF (International Diabetes Federation), the number has reached 300 million in 2010, and the number will reach 336 million in 2030. More than 95% of them belong to type Ⅱ diabetes, and its pathological manifestations are Insulin resistance and the relative lack of insulin secretion caused by islet cell dysfunction form persistent hyperglycemia, usually caused by insulin resistance, and then the phenomenon of insufficient insulin secretion, that is, the treatment of insulin resistance is the key point in the treatment of type 2 diabetes. Insulin resistance is a state in which the normal dose of insulin produces less than its norma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/58A61K38/48A61K38/01A61P3/10A61K36/888A61K31/702
CPCA61K31/702A61K36/16A61K36/286A61K36/428A61K36/488A61K36/736A61K36/888A61K38/012A61K38/482A61K38/58A61K2236/19A61K2236/333A61K2236/39C12Y304/21062A61K2300/00
Inventor 焦大明谢立炎张磊宋志刚
Owner 青岛金海宝生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com